E2F1 and metabolic dysfunction-associated steatohepatitis: To further test whether inhibition of liver E2F1 also confers anti‐fibrosis action in diet‐induced MASH, we challenged mice with HFLMCD diet to induce liver inflammation and fibrosis prior to tail vein injection of Ad‐shLacZ versus Ad‐shE2f1.